IGC Pharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
IGC$0.20+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholder’s Equity
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY
| Three months ended September 30, 2024 | Number of Common Shares | Common Stock and Additional Paid in Capital ($) | Accumulated Deficit ($) | Accumulated Other Comprehensive Loss ($) | Total Stockholders’ Equity ($) |
|---|---|---|---|---|---|
| Balances as of June 30, 2024 | 75,636 | 127,349 | (116,043) | (3,426) | 7,880 |
| Common stock-based compensation & expenses, net | - | 434 | - | - | 434 |
| Share money received but not allotted | - | 427 | - | - | 427 |
| Issuance of common stock through offering (net of expenses) | 1,000 | 368 | - | - | 368 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (1,717) | - | (1,717) |
| Foreign currency translation adjustments | - | - | - | (15) | (15) |
| Reclassification due to the liquidation of Subsidiaries | - | - | - | - | - |
| Balances as of September 30, 2024 | 76,636 | 128,578 | (117,760) | (3,441) | 7,377 |
| Balances as of June 30, 2025 | 84,141 | 131,920 | (122,343) | (3,499) | 6,078 |
| Common stock-based compensation & expenses, net | - | 742 | - | - | 742 |
| Share money received but not allotted | - | - | - | - | - |
| Issuance of common stock through offering (net of expenses) | 7,818 | 3,112 | - | - | 3,112 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (1,821) | - | (1,821) |
| Foreign currency translation adjustments | - | - | - | (19) | (19) |
| Reclassification due to the liquidation of Subsidiaries | - | - | 1,336 | (1,336) | - |
| Balances as of September 30, 2025 | 91,959 | 135,774 | (122,828) | (4,854) | 8,092 |
| Six months ended September 30, 2024 | Number of Common Shares | Common Stock and Additional Paid in Capital ($) | Accumulated Deficit ($) | Accumulated Other Comprehensive Loss ($) | Total Stockholders’ Equity ($) |
|---|---|---|---|---|---|
| Balances as of March 31, 2024 | 66,691 | 124,409 | (113,665) | (3,423) | 7,321 |
| Common stock-based compensation & expenses, net | - | 867 | - | - | 867 |
| Share money received but not allotted | - | 427 | - | - | 427 |
| Issuance of common stock through offering (net of expenses) | 9,945 | 2,875 | - | - | 2,875 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (4,095) | - | (4,095) |
| Foreign currency translation adjustments | - | - | - | (18) | (18) |
| Reclassification due to the liquidation of Subsidiaries | - | - | - | - | - |
| Balances as of September 30, 2024 | 76,636 | 128,578 | (117,760) | (3,441) | 7,377 |
| Balances as of March 31, 2025 | 80,878 | 130,570 | (120,744) | (3,496) | 6,330 |
| Common stock-based compensation & expenses, net | - | 1,240 | - | - | 1,240 |
| Share money received but not allotted | - | - | - | - | - |
| Issuance of common stock through offering (net of expenses) | 11,081 | 3,964 | - | - | 3,964 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (3,420) | - | (3,420) |
| Foreign currency translation adjustments | - | - | - | (22) | (22) |
| Reclassification due to liquidation of Subsidiaries | - | - | 1,336 | (1,336) | - |
| Balances as of September 30, 2025 | 91,959 | 135,774 | (122,828) | (4,854) | 8,092 |
| September 30, 2025, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.